Simultaneous control of third-degree graft-versus-host disease and prevention of recurrence of juvenile myelomonocytic leukemia (JMML) with 6-mercaptopurine following fulminant JMML relapse early after KIR-mismatched bone marrow transplantation

J Pediatr Hematol Oncol. 2005 Dec;27(12):672-4. doi: 10.1097/01.mph.0000193471.91690.f4.

Abstract

The authors describe a young boy with juvenile myelomonocytic leukemia (JMML) who relapsed 45 days after HLA and killer immunoglobulin-like receptor (KIR) mismatched unrelated donor bone marrow transplant (MMUD-BMT) and subsequently developed life-threatening graft-versus-host disease (GvHD). Treatment with 6-mercaptopurine (6-MP) appeared to control severe GvHD and possibly prevented recurrence of leukemic relapse.

Publication types

  • Case Reports

MeSH terms

  • Antimetabolites, Antineoplastic / therapeutic use*
  • Busulfan / administration & dosage
  • Cyclophosphamide / administration & dosage
  • Graft vs Host Disease / drug therapy*
  • Graft vs Leukemia Effect
  • HLA-B Antigens / genetics
  • HLA-B52 Antigen
  • HLA-C Antigens / genetics
  • Hematopoietic Stem Cell Transplantation*
  • Histocompatibility*
  • Humans
  • Infant
  • Leukemia, Myelomonocytic, Acute / drug therapy*
  • Leukemia, Myelomonocytic, Acute / therapy
  • Male
  • Melphalan / administration & dosage
  • Mercaptopurine / therapeutic use*
  • Receptors, Immunologic / genetics*
  • Receptors, KIR
  • Remission Induction
  • Secondary Prevention
  • Transplantation Conditioning
  • Transplantation, Homologous

Substances

  • Antimetabolites, Antineoplastic
  • HLA-B Antigens
  • HLA-B52 Antigen
  • HLA-C Antigens
  • HLA-C*12 antigen
  • HLA-C*15 antigen
  • HLA-C*70 antigen
  • Receptors, Immunologic
  • Receptors, KIR
  • Cyclophosphamide
  • Mercaptopurine
  • Busulfan
  • Melphalan